GERN
NASDAQ · Biotechnology
Geron Corp
$1.26
+0.03 (+2.44%)
Open$1.25
Previous Close$1.23
Day High$1.31
Day Low$1.23
52W High$2.01
52W Low$1.04
Volume—
Avg Volume14.60M
Market Cap808.32M
P/E Ratio—
EPS$-0.10
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+1,408.7% upside
Current
$1.26
$1.26
Target
$19.01
$19.01
$12.94
$19.01 avg
$24.33
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 193.86M | 153.95M | 141.15M |
| Net Income | -88,071,351 | -36,660,557 | -32,364,939 |
| Profit Margin | -45.4% | -23.8% | -22.9% |
| EBITDA | -71,834,733 | -44,322,691 | -40,350,825 |
| Free Cash Flow | — | -25,979,960 | -28,291,864 |
| Rev Growth | +574.2% | +15.1% | +6.9% |
| Debt/Equity | 1.10 | 0.42 | 0.59 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |